DOCSLIB.ORG

Myoclonus-Dystonia and Ε-Sarcoglycan — Neurodevelopment, Channel, and Signaling Dysfunction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Myoclonus-Dystonia and Ε-Sarcoglycan — Neurodevelopment, Channel, and Signaling Dysfunction REVIEW Twenty Years on: Myoclonus-Dystonia and ε-Sarcoglycan — Neurodevelopment, Channel, and Signaling Dysfunction Elisa Menozzi, MD,1,2 Bettina Balint, MD,2,3 Anna Latorre, MD,2,4 Enza Maria Valente, MD, PhD,5,6 John C. Rothwell, PhD,2 and Kailash P. Bhatia, MD, FRCP2* 1Department of Biomedical, Metabolic and Neural Sciences, University-Hospital of Modena and Reggio Emilia, Modena, Italy 2Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK 3Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany 4Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy 5Department of Molecular Medicine, University of Pavia, Pavia, Italy 6Neurogenetics Unit, IRCCS Santa Lucia Foundation, Rome, Italy ABSTRACT: Myoclonus-dystonia is a clinical syndrome epsilon-sarcoglycan gene–related myoclonus-dystonia, characterized by a typical childhood onset of myoclonic jerks these conditions can be collectively classified as “myoclonus- and dystonia involving the neck, trunk, and upper limbs. Psy- dystonia syndromes.” In the present article, we present chiatric symptomatology, namely, alcohol dependence and myoclonus-dystonia caused by epsilon-sarcoglycan gene phobic and obsessive-compulsive disorder, is also part of mutations, with a focus on genetics and underlying the clinical picture. Zonisamide has demonstrated effective- disease mechanisms. Second, we review those conditions ness at reducing both myoclonus and dystonia, and deep falling within the spectrum of myoclonus-dystonia syn- brain stimulation seems to be an effective and long-lasting dromes, highlighting their genetic background and therapeutic option for medication-refractory cases. In a sub- involved pathways. Finally, we critically discuss the normal set of patients, myoclonus-dystonia is associated with path- and pathological function of the epsilon-sarcoglycan gene ogenic variants in the epsilon-sarcoglycan gene, located on and its product, suggesting a role in the stabilization of the chromosome 7q21, and up to now, more than 100 different dopaminergic membrane via regulation of calcium homeo- pathogenic variants of the epsilon-sarcoglycan gene have stasis and in the neurodevelopmental process involving been described. In a few families with a clinical phenotype the cerebello-thalamo-pallido-cortical network. © 2019 resembling myoclonus-dystonia associated with distinct clini- International Parkinson and Movement Disorder Society cal features, variants have been identified in genes involved in novel pathways such as calcium channel regulation and Key Words: epsilon-sarcoglycan; genetics; myoclonus- neurodevelopment. Because of phenotypic similarities with dystonia; pathophysiology In 1983 the first description of a clinical syndrome “inherited myoclonus-dystonia.”1-3 Myoclonus-dystonia is characterized by myoclonus as the most prominent sign a rare condition, with an estimated prevalence of about and dystonia was provided, subsequently identified as 2 per 1.000.000 in Europe.4 Usually presenting in early --------------------------------------------------------- childhood and following a benign course, it was described *Correspondence to: Professor Kailash P. Bhatia, Department of to follow an autosomal-dominant pattern with variable Clinical and Movement Neurosciences, UCL Queen Square Institute of penetrance and expression.2 Twenty years ago, the first Neurology, Box 13, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK; E-mail: [email protected] locus for myoclonus-dystonia was mapped to chromo- somal region 7q21-q31.5-8 Two years later, heterozygous Relevant conflicts of interest/financial disclosures: The authors declare no financial disclosures/conflict of interest related to the present study. pathogenic variants in the epsilon-sarcoglycan (SGCE)gene 9 Funding agencies: The authors declare no funding sources for the pre- were reported to be causative for myoclonus-dystonia, sent study. implicating a member of the sarcoglycan family generally Received: 1 February 2019; Revised: 19 June 2019; Accepted: 14 associated with muscular dystrophies was involved in the July 2019 pathogenesis of a central nervous system (CNS) disorder.9 SGCE Published online 00 Month 2019 in Wiley Online Library From then, mutational screenings for in cohorts of (wileyonlinelibrary.com). DOI: 10.1002/mds.27822 patients presenting with myoclonus-dystonia have revealed Movement Disorders, 2019 1 MENOZZI ET AL that SGCE is the main causative gene for this syn- in pediatric cases, in whom it may be the sole presenting drome.10,11 As a consequence, the designation DYT-SGCE feature.35,36 Although isolated writer’s cramp presenting (OMIM 604149) now replaces the classic locus symbol as the first manifestation of SGCE-MD in early adult- 36 DYT11.12,13 hood has been reported, a screening of 43 patients with Over the years, patients presenting with a combination simple or complex writer’s cramp failed to identify any 49 of features typical of SGCE-related-myoclonus-dystonia association with SGCE mutations. Other studies also and additional distinct aspects have been reported to failed to identify SGCE mutations in patients with differ- carry pathogenic or likely pathogenic variants in genes ent subtypes of focal, segmental, or generalized dysto- 50,51 52 involved in neurodevelopment, channel, and signaling nia ; hence, except for pediatric writer’s cramp, pathways. As these genetic conditions share a number of SGCE mutation analysis is not recommended in sporadic clinical features with SGCE-related-myoclonus-dystonia, isolated dystonia in the absence of myoclonic jerks, or they can collectively be included in the phenotypic spec- additional nonmotor features (see below).51 trum of myoclonus-dystonia syndromes. Amelioration of motor signs with alcohol is a classic fea- 53,54 The aim of the present article is to provide an overview of ture of SGCE-MD, likely because of the GABAergic the clinical syndrome of myoclonus-dystonia because of deficit caused by Purkinje cell dysfunction secondary to SGCE mutations, hereafter referred to as SGCE-myoclo- SGCE mutations (see below), which alcohol might improve 55 nus-dystonia (SGCE-MD), discussing the clinical and elec- by increasing GABAergic transmission. The disease trophysiological features and the current therapeutic course of SGCE-MD is generally benign, with variable pro- 20,56 options, and highlighting the genetic background and gression. Spontaneous remission has been found at a underlying disease mechanisms. We then describe the con- rate of 5% of patients for myoclonus and in 22% for dysto- ditions within the spectrum of myoclonus-dystonia syn- nia, especially during childhood and adolescence,31 but also 57 dromes, focusing on their genetic basis and involved in early adulthood. Therefore, this variability should be pathways. Finally, as identifying different genetic causes taken into account when invasive therapeutic options are associated with similar phenotypes may provide new clues considered.31 to pathophysiology,14 we discuss and compare the patho- Psychiatric symptomatology is part of the clinical 54,58-63 physiological mechanisms of SGCE-MD in light of the spectrum of SGCE-MD. A recent multicenter study pathways unraveled by genetic determinants of myoclonus- investigated psychiatric symptomatology in a large cohort dystonia syndromes. of SGCE-MD patients, showing that 65% of manifesting carriers had at least 1 psychiatric diagnosis, one and a half times more than population estimates.64 Among them, SGCE-MD: A Clinical Overview specific phobias and social phobia were the most common diagnoses, followed by alcohol dependence and obsessive- Clinical Spectrum: compulsive disorder.64 Anxiety and depression have also Motor and Neuropsychiatric Features been frequently reported.62,63,65 As few studies failed to SGCE-MD usually manifests in childhood, with a mean detect any psychiatric symptoms assessing patients by age of onset of 6 years,15 and earlier onset is associated clinical scales rather than comprehensive diagnostic with female sex.16 Although rare, very early onset interviews,58,62 we would discourage the use of these tools (before 1 year)17-20 and onset in early adulthood (21 to in the clinical practice. Whether psychiatric symptomatol- 41 years)18,21-24 or after 40 years25,26 have also been ogy represents the expression of a pleiotropic function of reported. The predominant motor sign in SGCE-MD is the SGCE gene in the CNS or is secondary to motor signs myoclonus, presenting with very brief, “lightning-like” or is still debated.59,60,64 Some studies have shown an excess “tic-tac” jerks, typically involving the upper part of the of psychiatric symptoms in manifesting SGCE carriers ver- body (neck, trunk, limb), more in the proximal than distal sus asymptomatic subjects, including nonmanifesting car- muscles.27,28 Less frequently, other body parts, such as the riers and normal controls,59,64 and others did not report face,7,29-31 larynx,30-33 and lower limbs,16,20,22,23,31,34-38 any difference between SGCE carriers and noncarriers.66 can be affected. The myoclonic jerks may be present at rest but are typically aggravated or elicited by action, posture, SGCE and psychological stress.15,20,31 It is important to note that Positive and Negative Predictors for -MD a subset of patients can present with postural tremor of the Although SGCE is the main causative gene for upper limbs,39,40 which is often clinically indistinguishable myoclonus-dystonia,11
Load more

Recommended publications
  • Cover Petra B
    UvA-DARE (Digital Academic Repository) The role of Polycomb group proteins throughout development : f(l)avoring repression van der Stoop, P.M. Link to publication Citation for published version (APA): van der Stoop, P. M. (2009). The role of Polycomb group proteins throughout development : f(l)avoring repression. Amsterdam: Nederlands Kanker Instituut - Antoni Van Leeuwenhoekziekenhuis. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl) Download date: 27 Oct 2019 Chapter 4 Ubiquitin E3 Ligase Ring1b/Rnf2 of Polycomb Repressive Complex 1 Contributes to Stable Maintenance of Mouse Embryonic Stem Cells Petra van der Stoop*, Erwin A. Boutsma*, Danielle Hulsman, Sonja Noback, Mike Heimerikx, Ron M. Kerkhoven, J. Willem Voncken, Lodewyk F.A. Wessels, Maarten van Lohuizen * These authors contributed equally to this work Adapted from: PLoS ONE (2008) 3(5): e2235 Ring1b regulates ES cell fate Ubiquitin E3 Ligase Ring1b/Rnf2 of Polycomb Repressive Complex 1 Contributes to Stable Maintenance of Mouse Embryonic Stem Cells Petra van der Stoop1*, Erwin A.
    [Show full text]
  • SGCE Rabbit Pab
    Leader in Biomolecular Solutions for Life Science SGCE Rabbit pAb Catalog No.: A5330 Basic Information Background Catalog No. This gene encodes the epsilon member of the sarcoglycan family. Sarcoglycans are A5330 transmembrane proteins that are components of the dystrophin-glycoprotein complex, which link the actin cytoskeleton to the extracellular matrix. Unlike other family Observed MW members which are predominantly expressed in striated muscle, the epsilon 55kDa sarcoglycan is more broadly expressed. Mutations in this gene are associated with myoclonus-dystonia syndrome. This gene is imprinted, with preferential expression from Calculated MW the paternal allele. Alternatively spliced transcript variants encoding different isoforms 49kDa/51kDa/52kDa have been found for this gene. A pseudogene associated with this gene is located on chromosome 2. Category Primary antibody Applications WB,IHC,IF Cross-Reactivity Human, Mouse Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 8910 O43556 IHC 1:50 - 1:200 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-317 of human SGCE (NP_003910.1). Synonyms SGCE;DYT11;ESG;epsilon-SG Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using SGCE antibody (A5330) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020).
    [Show full text]
  • 2021 Code Changes Reference Guide
    Boston University Medical Group 2021 CPT Code Changes Reference Guide Page 1 of 51 Background Current Procedural Terminology (CPT) was created by the American Medical Association (AMA) in 1966. It is designed to be a means of effective and dependable communication among physicians, patients, and third-party payers. CPT provides a uniform coding scheme that accurately describes medical, surgical, and diagnostic services. CPT is used for public and private reimbursement systems; development of guidelines for medical care review; as a basis for local, regional, and national utilization comparisons; and medical education and research. CPT Category I codes describe procedures and services that are consistent with contemporary medical practice. Category I codes are five-digit numeric codes. CPT Category II codes facilitate data collection for certain services and test results that contribute to positive health outcomes and quality patient care. These codes are optional and used for performance management. They are alphanumeric five-digit codes with the alpha character F in the last position. CPT Category III codes represent emerging technologies. They are alphanumeric five-digit codes with the alpha character T in the last position. The CPT Editorial Panel, appointed by the AMA Board of Trustees, is responsible for maintaining and updating the CPT code set. Purpose The AMA makes annual updates to the CPT code set, effective January 1. These updates include deleted codes, revised codes, and new codes. It’s important for providers to understand the code changes and the impact those changes will have to systems, workflow, reimbursement, and RVUs. This document is meant to assist you with this by providing a summary of the changes; a detailed breakdown of this year’s CPT changes by specialty, and HCPCS Updates for your reference.
    [Show full text]
  • Supplemental Table 1. List of Candidate Gene Filters Used in the Analysis of Exome Sequencing. MYOPATHY NEUROPATHY MND ABHD5
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Supplemental table 1. List of candidate gene filters used in the analysis of exome sequencing. MYOPATHY NEUROPATHY MND ABHD5 AAAS AAAS ACADL AARS1 AARS1 ACADM ABCA1 AGT ACADS ABCD1 ALAD ACADVL ABHD12 ALS2 ACTA1 ADCY6 ANG ADSSL1 AFG3L2 APEX1 AGL AIFM1 APOE AGPAT2 AMACR AR AGRN ANG ASAH1 AIRE AP1S1 ATM ALDOA APOA1 ATP7A ALG14 APTX ATXN2 ALG2 ARHGEF10 ATXN3 ALG3 ARL6IP1 B4GALT6 ANKRD2 ARSA BCL11B ANO5 ASAH1 BCL6 ASCC1 ATL1 BICD2 ATGL ATL3 BSCL2 ATP2A1 ATM C19orf12 ATRN ATXN1 C9orf72 B3GALNT2 ATXN10 CCS B3GNT2 ATXN2 CDH13 BAG3 ATXN3 CDH22 BIN1 ATXN7 CHCHD10 BSCL2 B2M CHMP2B BVES B4GALNT1 CNTF CACNA1S BAG3 CNTN4 CAPN3 BCKDHB CNTN6 CASQ1 BSCL2 CRIM1 CAV1 C12orf65 CRYM CAV3 C9orf72 CSNK1G3 CAVIN1 CLP1 CST3 CCDC78 CNTNAP1 CUL4B CDKN1C COX10 CYP2D6 CFL2 COX6A1 DAO Grunseich C, et al. J Neurol Neurosurg Psychiatry 2021;0:1–11. doi: 10.1136/jnnp-2020-325437 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry CHAT CPOX DCAF15 CHCHD10 CRYAB DCTN1 CHD7 CTDP1 DIAPH3 CHKB CTSA DISC1 CHN1 CYP27A1 DNAJB2 CHRM3 DARS2 DOC2B CHRNA1 DDHD1 DPP6 CHRNB1 DGUOK DYNC1H1 CHRND DHH EFEMP1 CHRNE DHTKD1 ELP3 CIDEC DMD EPHA4 CLCN1 DNAJB2 EWSR1 CLN3 DNAJC3 EXOSC3 CNBP DNM2 FBLN5 CNTN1 DYNC1H1 FBXO38 COA3 EGR2 FEZF2 COL12A1 EMD FGGY COL13A1 ERCC6 FIG4 COL6A ERCC8 FUS COL6A1 FAH GARS1 COL6A2 FAM126A GBE1 COL6A3 FBLN5 GMPPA COL9A3 FGD4 GRB14 COLQ FGF14 GRN COX10 FIG4 HEXA COX15 FLNC HFE CPT2 FLRT1 HINT1 CRAT FLVCR1 HSPB1 CRPPA FMR1 HSPB3 CRYAB FUS HSPB8 CTNS FXN IGHMBP2 DAG1 GALC ITPR2 DECR1 GAN KDR DES GARS1 KIFAP3 DGUOK GBA2 KLHL9 DIH1 GBE1 LAMA2 DMD GDAP1 LAS1L DMPK GJB1 LIF DNAJB6 GJB3 LIPC DNAJC19 GLA LOX Grunseich C, et al.
    [Show full text]
  • Prenatal Testing Requisition Form
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 PRENATAL COMPREHENSIVE REQUISITION FORM PATIENT INFORMATION NAME (LAST,FIRST, MI): DATE OF BIRTH (MM/DD/YY): HOSPITAL#: ACCESSION#: REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: SAMPLE INFORMATION CLINICAL INDICATION FETAL SPECIMEN TYPE Pregnancy at risk for specific genetic disorder DATE OF COLLECTION: (Complete FAMILIAL MUTATION information below) Amniotic Fluid: cc AMA PERFORMING PHYSICIAN: CVS: mg TA TC Abnormal Maternal Screen: Fetal Blood: cc GESTATIONAL AGE (GA) Calculation for AF-AFP* NTD TRI 21 TRI 18 Other: SELECT ONLY ONE: Abnormal NIPT (attach report): POC/Fetal Tissue, Type: TRI 21 TRI 13 TRI 18 Other: Cultured Amniocytes U/S DATE (MM/DD/YY): Abnormal U/S (SPECIFY): Cultured CVS GA ON U/S DATE: WKS DAYS PARENTAL BLOODS - REQUIRED FOR CMA -OR- Maternal Blood Date of Collection: Multiple Pregnancy Losses LMP DATE (MM/DD/YY): Parental Concern Paternal Blood Date of Collection: Other Indication (DETAIL AND ATTACH REPORT): *Important: U/S dating will be used if no selection is made. Name: Note: Results will differ depending on method checked. Last Name First Name U/S dating increases overall screening performance. Date of Birth: KNOWN FAMILIAL MUTATION/DISORDER SPECIFIC PRENATAL TESTING Notice: Prior to ordering testing for any of the disorders listed, you must call the lab and discuss the clinical history and sample requirements with a genetic counselor.
    [Show full text]
  • Neuromuscular Disorders
    Neuromuscular Disorders neuromuscular disorders panel, as well as an expanded 78-gene panel for the following conditions depending on the EGL offers a 46-gene neuromuscular disorders panel, as well as an expanded 78-gene panel, depending on the specificity of a patient's phenotype. Other phenotype-specific panels are available for limb-girdle muscular dystrophy (34 Neuromuscular Disorders Genes Included on the Expanded Neuromuscular Disorders Panel* ACTA1 CHRNA1 DAG1 FLNC LMNA PLEKHG5 SCN4A TNNI2 AMPD1 CHRNB1 DES GAA MTM1 PMM2 SEPN1 TNNT1 ANO5 CHRND DMD GLE1 MTMR14 POMGNT1 SGCA TPM2 BAG3 CHRNE DNM2 GNE MUSK POMT1 SGCB TPM3 BIN1 CHRNG DOK7 IGHMBP2 MYH2 POMT2 SGCD TRIM32 BSCL2 COL6A1 DYSF ISPD MYH7 PTRF SGCE TTN CAPN3 COL6A2 EMD ITGA7 MYOT PYGM SGCG VCP CAV3 COL6A3 FHL1 LAMA2 NEB RAPSN SIL1 VRK1 CFL2 COLQ FKRP LARGE PABPN1 RYR1 SYNE1 CHAT CRYAB FKTN LDB3 PLEC RYR2 TCAP *Bolded genes are also found on the 46-gene neuromuscular disorders panel. Please note that deletion/duplication analysis is not completed for all genes in the panel. Some genes on this panel are associated with additional phenotypes. All genes on the next generation sequencing panel may be ordered separately. Genes included on panels are subject to change. Test Code Test Name CPT®** Code(s) 81400 (x1), 81401 (x1), 81404 (x1), MNEU1 Neuromuscular Disorders: Sequencing Panel 81405 (x1), 81406 (x1), 81407 (x1), 81408 (x1) 81161 (x1), 81404 (x1), 81405 (x1), DNEU1 Neuromuscular Disorders: Deletion/Duplication Panel 81406 (x1), 81408 (x1) MM360 Expanded Neuromuscular Disorders:
    [Show full text]
  • NGS Panels 2020
    NGS Panels 2020 BENEFIT FROM OUR MEDICAL EXPERTISE AND STREAMLINED GENETIC TESTING NGS Panels 2020 Benefit from our Medical Expertise and Streamlined Genetic Testing CENTOGENE is fully committed to bringing the best possible diagnostic solutions to our patients and their families. We always strive to incorporate the latest in-house findings and medical research in our products to improve and ease the diagnostic odyssey of rare disease patients. To reflect the fast-growing knowledge of complex associations of genes with diseases as well as to maximize clinical sensitivity, we have updated and significantly redesigned our Next Generation Sequencing (NGS) gene panels. The gene composition of each panel has been revised to meet the latest gene discoveries as well as to provide the highest clinical validity. Additionally, we have minimized complexity and removed redundancy in the panel portfolio by creating phenotype-directed diagnostic panels, which are the most comprehensive and include all relevant genes necessary for differential diagnosis of syndromes with overlapping phenotype, therefore allowing the diagnosis of diseases that otherwise would be missed. This principle increases the clinical utility, de-risks panel choice, increases cost-effectiveness, and ultimately simplifies the diagnostic process. When choosing one of our NGS panels, feel confident that you will receive high-quality sequencing combined with best data analysis and interpretation, which are documented in comprehensive medical reports. As always, CENTOGENE and our Customer
    [Show full text]
  • The Genetics of Primary Dystonias and Related Disorders
    Brain (2002), 125, 695±721 INVITED REVIEW The genetics of primary dystonias and related disorders Andrea H. NeÂmeth The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Headington, Oxford OX3 7BN, UK E-mail: [email protected] Summary Dystonias are a heterogeneous group of disorders which dystonia (DYT1), focal dystonias (DYT7) and mixed dys- are known to have a strong inherited basis. This review tonias (DYT6 and DYT13), dopa-responsive dystonia, details recent advances in our understanding of the gen- myoclonus dystonia, rapid-onset dystonia parkinsonism, etic basis of dystonias, including the primary dystonias, Fahr disease, Aicardi±Goutieres syndrome, Haller- the `dystonia-plus' syndromes and heredodegenerative vorden±Spatz syndrome, X-linked dystonia parkin- disorders. The review focuses particularly on clinical sonism, deafness±dystonia syndrome, mitochondrial and genetic features and molecular mechanisms. dystonias, neuroacanthocytosis and the paroxysmal dys- Conditions discussed in detail include idiopathic torsion tonias/dyskinesias. Keywords: dystonia; L-dopa; parkinsonism; myoclonus; mitochondria Abbreviations: DRD = dopa-responsive dystonia; ITD = idiopathic torsion dystonia; PDJ = juvenile onset Parkinson's disease; PKC = paroxysmal kinesigenic choreoathetosis; PNKD = paroxysmal non-kinesigenic dyskinesia; TH = tyrosine hydroxylase Introduction Dystonia is a disorder of movement caused by `involuntary, (Fahn et al., 1998). Clinically, this is useful because onset of sustained muscle contractions affecting one or more sites of dystonia in the limbs, particularly the legs, is more likely to the body, frequently causing twisting and repetitive move- be associated with spread to other body parts and has ments, or abnormal postures' (Fahn et al., 1987, 1998). The important implications for treatment, management and prog- genetic contribution to the development of dystonia has been nosis, since generalized dystonia is usually much more recognized for many years, but it is only recently that some of disabling.
    [Show full text]
  • Genetic Testing Medical Policy – Genetics
    Genetic Testing Medical Policy – Genetics Please complete all appropriate questions fully. Suggested medical record documentation: • Current History & Physical • Progress Notes • Family Genetic History • Genetic Counseling Evaluation *Failure to include suggested medical record documentation may result in delay or possible denial of request. PATIENT INFORMATION Name: Member ID: Group ID: PROCEDURE INFORMATION Genetic Counseling performed: c Yes c No **Please check the requested analyte(s), identify number of units requested, and provide indication/rationale for testing. 81400 Molecular Pathology Level 1 Units _____ c ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (e.g., medium chain acyl dehydrogenase deficiency), K304E variant _____ c ACE (angiotensin converting enzyme) (e.g., hereditary blood pressure regulation), insertion/deletion variant _____ c AGTR1 (angiotensin II receptor, type 1) (e.g., essential hypertension), 1166A>C variant _____ c BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (e.g., maple syrup urine disease, type 1A), Y438N variant _____ c CCR5 (chemokine C-C motif receptor 5) (e.g., HIV resistance), 32-bp deletion mutation/794 825del32 deletion _____ c CLRN1 (clarin 1) (e.g., Usher syndrome, type 3), N48K variant _____ c DPYD (dihydropyrimidine dehydrogenase) (e.g., 5-fluorouracil/5-FU and capecitabine drug metabolism), IVS14+1G>A variant _____ c F13B (coagulation factor XIII, B polypeptide) (e.g., hereditary hypercoagulability), V34L variant _____ c F2 (coagulation factor 2) (e.g.,
    [Show full text]
  • Proquest Dissertations
    mn u Ottawa l.'Univcrsilc can.ifficn/ic Canada's university FACULTE DES ETUDES SUPERIEURES 11=1 FACULTY OF GRADUATE AND ET POSTOCTORALES U Ottawa POSDOCTORAL STUDIES L'Urriversittf canadienne (Canada's university Fabin Han AUTEUR DE LA THESE / AUTHOR OF THESIS Ph.D. (Microbiology and Immunology) GRADE/DEGREE Department of Biochemistry, Microbiology and Immunology Characterization of the Genes for Myoclonus-Dystonia TITRE DE LA THESE / TITLE OF THESIS Dennis Bulman EXAMINATEURS (EXAMINATRICES) DE LA THESE /THESIS EXAMINERS John Bell Peter Ray Robert Korneluk Catherine Tsilfidis Gary W. Slater. Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies Characterization of the Genes for Myoclonus-Dystonia By Fabin Han Thesis Submitted to the School of Graduate Studies in Partial Fulfillment of the Requirements for the Degree of Doctorate of Philosophy Department of Biochemistry, Microbiology and Immunology, Graduate Collaborative Program in Human and Molecular Genetics, Faculty of Medicine University of Ottawa Copyright by Fabin Han, 2007 Ottawa, Canada Library and Bibliotheque et 1*1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A0N4 Ottawa ON K1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-49354-0 Our file Notre reference ISBN: 978-0-494-49354-0 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing
    [Show full text]
  • The Effect of Mechanical Force on Gene Expression of Human Bladder Smooth Muscle Cells" (2012)
    Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Biomedical Studies Student Scholarship Student Dissertations, Theses and Papers 6-2012 The ffecE t of Mechanical Force on Gene Expression of Human Bladder Smooth Muscle Cells Christopher A. Callan Philadelphia College of Osteopathic Medicine, [email protected] Follow this and additional works at: http://digitalcommons.pcom.edu/biomed Part of the Molecular Genetics Commons, and the Urogenital System Commons Recommended Citation Callan, Christopher A., "The Effect of Mechanical Force on Gene Expression of Human Bladder Smooth Muscle Cells" (2012). PCOM Biomedical Studies Student Scholarship. Paper 36. This Thesis is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Biomedical Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE Philadelphia, Pennsylvania The Effect Of Mechanical Force on Gene Expression of Human Bladder Smooth Muscle Cells A thesis submitted in partial fulfillnment of the requirements for the degree of MASTER OF BIOMEDICAL SCIENCE by Christopher A. Callan June 2012 We approve the thesis of Christopher A. Callan _______________________________________________________________________ Edward J. Macarak, Ph.D. Date Chairman; Department of Anatomy and Cell Biology University of Pennsylvania School of Dental Medicine Thesis
    [Show full text]
  • Multitarget Deep Brain Stimulation for Clinically Complex Movement Disorders
    CASE REPORT Multitarget deep brain stimulation for clinically complex movement disorders Tariq Parker, MRCS, Ashley L. B. Raghu, BSc(Hons), James J. FitzGerald, FRCS(SN), Alexander L. Green, FRCS(SN), and Tipu Z. Aziz, FMedSci Oxford Functional Neurosurgery, Nuffield Department of Surgical Sciences, University of Oxford, United Kingdom Deep brain stimulation (DBS) of single-target nuclei has produced remarkable functional outcomes in a number of move- ment disorders such as Parkinson’s disease, essential tremor, and dystonia. While these benefits are well established, DBS efficacy and strategy for unusual, unclassified movement disorder syndromes is less clear. A strategy of dual pal- lidal and thalamic electrode placement is a rational approach in such cases where there is profound, medically refractory functional impairment. The authors report a series of such cases: midbrain cavernoma hemorrhage with olivary hyper- trophy, spinocerebellar ataxia-like disorder of probable genetic origin, Holmes tremor secondary to brainstem stroke, and hemiballismus due to traumatic thalamic hemorrhage, all treated by dual pallidal and thalamic DBS. All patients demon- strated robust benefit from DBS, maintained in long-term follow-up. This series demonstrates the flexibility and efficacy, but also the limitations, of dual thalamo-pallidal stimulation for managing axial and limb symptoms of tremors, dystonia, chorea, and hemiballismus in patients with complex movement disorders. https://thejns.org/doi/abs/10.3171/2019.11.JNS192224 KEYWORDS deep brain stimulation; dystonia; essential tremor; thalamus; globus pallidus; functional neurosurgery EEP brain stimulation (DBS) surgery for the treat- Her condition progressed to developing speech difficul- ment of movement disorders usually employs stim- ties, left-sided one-and-a-half syndrome, and a bilateral ulation at a single site in one or both hemispheres.
    [Show full text]